Alert detail

LCD L37832: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — CGS

Policy ID: LCD-L37832Specialty: OncologyAdded: 6/5/2026Effective: October 23, 2025lcd
Routine

What changed

New BCI test coverage effective 10/23/2025 impacts billing.

Who’s affected: Oncology billing teams · Effective: October 23, 2025

Affected codes

Codes81518

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 4 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.

LCD L37832: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — CGS